Inhibrx Sets INBRX-106 Phase 2 HNSCC Data Readout, Adding Near-Term Binary Catalyst

What happened

Inhibrx Biosciences announced a webcast on September 8 to present primary endpoint results from the INBRX-106 Phase 2 first-line head and neck squamous cell carcinoma study, moving the program's interpretability timeline earlier than the '2H 2026' previously signaled. The master report had classified INBRX-106 as immature optionality with no valuation credit, focusing the investment thesis on ozekibart's planned Q2 2026 BLA and its hepatotoxicity overhang. This readout now introduces a discrete catalyst that could either validate the second asset or reinforce the single-asset concentration risk. The stock has been volatile, trading around $80 after a >500% run from early 2025, reflecting high expectations for the ozekibart filing. Investors must now weigh the potential upside from positive INBRX-106 data against the risk of a negative readout that could dampen pipeline sentiment.

Implication

Over the next few quarters, the INBRX-106 readout will determine whether the program justifies further Phase 3 investment and contributes to valuation. A positive result would increase the company's strategic value but also accelerate cash needs; a negative result would leave the equity more dependent on ozekibart's regulatory path, where liver safety remains the key risk.

Thesis delta

The previous thesis held INBRX-106 as non-interpretable until 2H 2026, so its value was excluded. The upcoming primary endpoint readout compresses that timeline and creates a near-term binary event that could either add pipeline value or reinforce the single-asset risk profile. We maintain WAIT but now treat the INBRX-106 data as a potential thesis-changing catalyst for both upside and downside.